Page last updated: 2024-08-18

pyrroles and Fatty Liver, Nonalcoholic

pyrroles has been researched along with Fatty Liver, Nonalcoholic in 34 studies

Research

Studies (34)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's23 (67.65)24.3611
2020's11 (32.35)2.80

Authors

AuthorsStudies
Honda, A; Ishii, I; Kamata, S; Machida, Y; Nemoto, A; Oyama, T; Satta, C; Terasawa, K; Uchii, K1
Afarin, R; Akbari, R; Behdarvand, T; Jalali, MT; Mohammadtaghvaei, N; Yaghooti, H1
Eqbal, F; Rehman, H; Shuja, SH1
Boeckmans, J; Buyl, K; De Kock, J; M Rodrigues, R; Natale, A; Rogiers, V; Rombaut, M; Vanhaecke, T1
Chhina, RS; Goyal, O; Goyal, P1
Alonso, C; Bedossa, P; Bhat, M; Caffrey, R; Giri, SR; Jain, MR; Koduru, SV; Kumar, DP; Marioneaux, J; Philip, B; Santhekadur, PK; Sanyal, AJ1
Chhina, RS; Goyal, O; Goyal, P; Kaur, J; Nohria, S; Sharma, S; Sood, A1
Awasty, V; Chalasani, N; Cusi, K; Gawrieh, S; Kowdley, KV; Lai, M; Loo, N; Mohseni, R; Noureddin, M; Parmar, D; Patel, P; Schiff, E1
Lai, X; Wu, H; Yang, SH; Yi, ZJ1
Francque, S1
Jagdish, RK; Kulkarni, A; Kumar, K1
Bhoi, B; Das, N; Giri, SR; Jain, MR; Kadam, S; Karmakar, E; Patel, H; Patel, PR; Ranvir, R; Rath, A; Rathod, R; Roy, SS; Swain, P; Trivedi, C; Wahli, W1
Abdelsalam, RM; Al-Shorbagy, MY; El-Ansary, MR; Hassan, A; Hassan, NF; Nada, SA1
Jaiswal, A; Kaul, U; Manjunath, K; Parmar, D; Parmar, K; Patil, KP; Shah, M1
Farrell, GC; Gan, LT; Haigh, WG; Ioannou, G; Larter, CZ; Teoh, NC; Van Rooyen, DM; Yeh, MM1
Athyros, VG; Karagiannis, A; Katsiki, N1
Athyros, VG; Karagiannis, A; Katsiki, N; Mikhailidis, DP1
Droog, S; Havekes, LM; Maas, AC; Offerman, EH; Pieterman, EJ; Princen, HM; van den Hoek, AM; van den Hoogen, RM; van der Hoorn, JW; van Nieuwkoop, A1
Aramin, H; Eslami, L; Malekzadeh, R; Merat, S; Nasseri-Moghaddam, S1
Farrell, GC; Haigh, WG; Ioannou, GN; Savard, C; Teoh, NC; Van Rooyen, DM; Yeh, MM1
Dubrovins'ka, TV; Skrypnyk, IM1
Eguchi, Y; Fujita, K; Honda, Y; Hyogo, H; Imajo, K; Kessoku, T; Kirikoshi, H; Mawatari, H; Nakajima, A; Nozaki, Y; Ogawa, Y; Ono, M; Saito, S; Sumida, Y; Taguri, M; Tomeno, W; Wada, K; Yoneda, M1
Ahmadi, N; Budoff, MJ; Foster, T; Gordon, C; Guerci, AD; Saab, S1
Alegret, M; Ađalsteisson, GS; Laguna, JC; Merlos, M; Rebollo, A; Roglans, N; Vilà, L1
Allard, JP; Arendt, BM1
Amaral, C; Cipriano, A; Crisóstomo, J; Louro, T; Matafome, P; Monteiro, P; Nunes, E; Rodrigues, L; Seiça, R1
Ji, G; Jiang, Z; Leng, L; Liu, P; Zhao, X1
Hassanian, MA; Samy, W1
Chayama, K; Hyogo, H; Ishitobi, T; Kimura, Y; Maeda, S; Yamagishi, S1
Ajamieh, H; Chen, J; Chu, E; Farrell, G; Teoh, N; Wong, HJ; Yu, J1
Lonardo, A; Loria, P1
Gracia-Sancho, J1

Reviews

4 review(s) available for pyrroles and Fatty Liver, Nonalcoholic

ArticleYear
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide

2023
Anti-NASH Drug Development Hitches a Lift on PPAR Agonism.
    Cells, 2019, 12-21, Volume: 9, Issue:1

    Topics: Chalcones; Diabetes Mellitus, Type 2; Drug Development; Fatty Liver; Humans; Hypoglycemic Agents; Inflammation; Liver; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pioglitazone; Propionates; Pyrroles

2019
New dual peroxisome proliferator activated receptor agonist-Saroglitazar in diabetic dyslipidemia and non-alcoholic fatty liver disease: integrated analysis of the real world evidence.
    Cardiovascular diabetology, 2019, 06-17, Volume: 18, Issue:1

    Topics: Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Glycated Hemoglobin; Humans; Hypoglycemic Agents; Hypolipidemic Agents; India; Lipids; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction; Time Factors; Treatment Outcome

2019
Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
    The Cochrane database of systematic reviews, 2013, Dec-27, Issue:12

    Topics: Alanine Transaminase; Atorvastatin; Fatty Liver; Fenofibrate; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Non-alcoholic Fatty Liver Disease; Pyrroles; Simvastatin

2013

Trials

7 trial(s) available for pyrroles and Fatty Liver, Nonalcoholic

ArticleYear
Effect of 12-week of aerobic exercise on hormones and lipid profile status in adolescent girls with polycystic ovary syndrome: A study during COVID-19.
    Science & sports, 2023, Apr-04

    Topics: Actin Cytoskeleton; Actins; Adaptor Proteins, Signal Transducing; Adenocarcinoma; Adenosine Triphosphate; Adsorption; Adult; Africa, Eastern; Aged; Air Pollutants; Air Pollution; Air Pollution, Indoor; Alcohol Drinking; Allergens; Alzheimer Disease; Amyotrophic Lateral Sclerosis; Animals; Anti-Bacterial Agents; Antibodies; Antibodies, Immobilized; Antigen Presentation; Antigens, CD; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Antioxidants; Apoptosis; Aptamers, Nucleotide; Asthma; Asthma, Exercise-Induced; Atrophy; Autophagy; Azoospermia; Bacillus cereus; Bacterial Infections; Beclin-1; Bile Duct Neoplasms; Bile Ducts, Intrahepatic; Biofouling; Biological Monitoring; Biomarkers; Biomarkers, Tumor; Biosensing Techniques; Blastocyst; Bone Neoplasms; Bone Regeneration; Bronchoconstriction; Burkitt Lymphoma; C9orf72 Protein; Campylobacter; Campylobacter Infections; Campylobacter jejuni; Carcinogenesis; Carcinoma, Hepatocellular; Carcinoma, Pancreatic Ductal; Carcinoma, Squamous Cell; Cardiomyopathies; Caregivers; Carmine; Case-Control Studies; Catalysis; Cattle; Cause of Death; CCAAT-Enhancer-Binding Protein-alpha; CD8-Positive T-Lymphocytes; Cefepime; Cell Differentiation; Cell Line, Tumor; Cell Nucleus; Cell Transdifferentiation; Chelating Agents; Chemical and Drug Induced Liver Injury, Chronic; Chemoradiotherapy, Adjuvant; Child; Child, Preschool; China; Chlorquinaldol; Cholangiocarcinoma; Cholera; Chromatin; Clinical Trials as Topic; Cognitive Dysfunction; Cohort Studies; Colonic Neoplasms; Colorectal Neoplasms; Colorimetry; Cooking; Coordination Complexes; COVID-19; Creatinine; CRISPR-Cas Systems; Critical Care; Critical Illness; Cross-Sectional Studies; Cryopreservation; Cryoprotective Agents; Cysteine; Cytokines; Device Removal; Diet; Diet, High-Fat; Diet, Mediterranean; Dietary Supplements; Dimethyl Sulfoxide; Dipeptides; Disease Models, Animal; Dithiothreitol; DNA; DNA Repeat Expansion; DNA, Bacterial; DNA, Complementary; Dopamine; Electrochemical Techniques; Electrodes; Endocannabinoids; Environmental Exposure; Environmental Monitoring; Environmental Pollutants; Enzyme-Linked Immunosorbent Assay; Erlotinib Hydrochloride; Escherichia coli; Escherichia coli O157; Esophageal Neoplasms; Esophagitis, Peptic; Ethylene Glycol; Europium; Exanthema; Fallopian Tubes; Feces; Female; Fertilization in Vitro; Fluoresceins; Fluorescent Dyes; Follicle Stimulating Hormone; Follow-Up Studies; Food Microbiology; Forced Expiratory Volume; Forkhead Transcription Factors; Frontotemporal Dementia; G-Quadruplexes; Galactose; Gastroenteritis; Gastrointestinal Diseases; Gastrointestinal Microbiome; Gastrointestinal Neoplasms; Gastrointestinal Tract; Gene Frequency; Genetic Association Studies; Genetic Predisposition to Disease; Genital Neoplasms, Female; Genome-Wide Association Study; Genome, Viral; Genomics; Genotype; Glucose; Glutathione; Glycerol; Gold; Graphite; GTPase-Activating Proteins; Heat-Shock Proteins; Heme Oxygenase-1; Hepacivirus; Hepatitis C; Hepatocytes; Histamine; Histocompatibility Antigens Class II; Hoarseness; Hospice and Palliative Care Nursing; Humans; Hydrogen; Hydrogen Peroxide; Hydrogen Sulfide; Hydroxybenzoates; Hydroxyl Radical; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperthermia, Induced; Hysteroscopy; Immunoassay; Indigo Carmine; Inflammation; Inflammatory Bowel Diseases; Insulin Resistance; Intensive Care Units; Interleukin-11; Interleukin-6; Interleukins; Iodine Radioisotopes; Iran; Iridium; Islets of Langerhans; Kinetics; Lactation; Lactobacillus; Lactobacillus plantarum; Lamins; Latin America; Lead; Lectins; Leukopenia; Ligands; Limit of Detection; Lipopolysaccharides; Lipoprotein Lipase; Liver; Liver Cirrhosis; Liver Neoplasms; Lolium; Luminescent Measurements; Luminol; Lung; Luteinizing Hormone; Macrophages; Magnetic Phenomena; Magnetic Resonance Imaging; Male; Malnutrition; Maltose; Manganese Compounds; Maternal Nutritional Physiological Phenomena; Melatonin; Metabolic Engineering; Metal Nanoparticles; Metallocenes; Metaplasia; Methicillin-Resistant Staphylococcus aureus; Methylation; Mevalonic Acid; Mexico; Mice; Mice, Inbred C57BL; Mice, Transgenic; Microbial Sensitivity Tests; Microbiota; MicroRNAs; Milk; Mitomycin; Molecular Diagnostic Techniques; Molecular Docking Simulation; Monte Carlo Method; Moringa oleifera; Multiple Sclerosis; Muscle Strength; Muscle, Skeletal; Nanocomposites; Nanotubes, Carbon; Neoadjuvant Therapy; Neoplasms; Neurodegenerative Diseases; Neurotransmitter Agents; NF-E2-Related Factor 2; Nickel; Nitrogen Dioxide; Non-alcoholic Fatty Liver Disease; Nucleic Acid Amplification Techniques; Nucleic Acid Hybridization; Nucleocapsid Proteins; Nutritional Status; Obesity; Osteogenesis; Osteosarcoma; Oxidation-Reduction; Oxides; Oxygen; Oxyquinoline; Pain; Palliative Care; Pancreatic Neoplasms; Pandemics; Particulate Matter; Peroxidase; Peroxidases; Phagocytosis; Phaseolus; Photothermal Therapy; Point-of-Care Systems; Polyethyleneimine; Polymers; Polymorphism, Single Nucleotide; Polysomnography; Postoperative Complications; Pregnancy; Pregnant Women; Prenatal Exposure Delayed Effects; Prevalence; Printing, Three-Dimensional; Probability; Probiotics; Prognosis; Prophages; Prospective Studies; Proteomics; Proto-Oncogene Proteins; Pseudomonas aeruginosa; Pseudomonas putida; Pulmonary Disease, Chronic Obstructive; Pulmonary Embolism; Pyridines; Pyrroles; Quality of Life; Quinolones; Rabbits; Rats; Rats, Sprague-Dawley; Reactive Oxygen Species; Real-Time Polymerase Chain Reaction; Receptors, Histamine; Receptors, Histamine H2; Recombinases; Rectal Neoplasms; Reperfusion Injury; Respiration; Respiratory Function Tests; Respiratory Rate; Respiratory Sounds; Retrospective Studies; rho GTP-Binding Proteins; Risk Assessment; Risk Factors; RNA; RNA, Messenger; RNA, Ribosomal, 16S; Robotic Surgical Procedures; Running; Rural Population; Saccharomyces cerevisiae; Salpingectomy; Sarcopenia; SARS-CoV-2; Seeds; Semen; Sensitivity and Specificity; Sepsis; Shock, Septic; Signal Transduction; Silicon Dioxide; Silver; Sirtuin 1; Skin Neoplasms; Sleep Apnea, Obstructive; Soil; Spain; Spectrum Analysis, Raman; Sperm Retrieval; Spermatozoa; Spirometry; Staphylococcus aureus; STAT3 Transcription Factor; Stereoisomerism; Sterilization, Tubal; Stroke Volume; Sulfadiazine; Sulfites; Superoxide Dismutase; Surface Plasmon Resonance; tau Proteins; Testis; Testosterone; Thioredoxin-Disulfide Reductase; Thyroid Neoplasms; Thyroidectomy; Trans-Activators; Transcription Factor AP-1; Treatment Outcome; Triazoles; Triclosan; Trifluridine; Tumor Microenvironment; Tumor Necrosis Factor-alpha; United States; Uracil; Vagina; Vegetables; Ventricular Function, Left; Ventricular Pressure; Vibrio cholerae; Vietnam; Virulence; Vital Capacity; Vitrification; Walking; Water; Water Pollutants, Radioactive; Whole Genome Sequencing; Wind; YAP-Signaling Proteins; Zeolites; Zinc Oxide

2023
Saroglitazar, a PPAR-α/γ Agonist, for Treatment of NAFLD: A Randomized Controlled Double-Blind Phase 2 Trial.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Adipose Tissue; Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Double-Blind Method; Elasticity Imaging Techniques; Female; gamma-Glutamyltransferase; Humans; Insulin Resistance; Liver; Magnetic Resonance Imaging; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Triglycerides

2021
[Optimization of long-term hypolipidemia treatment of patients with myocardial infarction in combination with non-alcoholic steatohepatitis].
    Georgian medical news, 2014, Issue:229

    Topics: Atorvastatin; Bilirubin; Fluorobenzenes; Heptanoic Acids; Humans; Hypolipidemic Agents; Lipids; Liver; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Rosuvastatin Calcium; Sulfonamides; Transaminases; Triglycerides; Ursodeoxycholic Acid

2014
LDL-migration index (LDL-MI), an indicator of small dense low-density lipoprotein (sdLDL), is higher in non-alcoholic steatohepatitis than in non-alcoholic fatty liver: a multicenter cross-sectional study.
    PloS one, 2014, Volume: 9, Issue:12

    Topics: Adult; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Azetidines; Cross-Sectional Studies; Ezetimibe; Female; Heptanoic Acids; Humans; Lipoproteins, LDL; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Factors

2014
Atorvastatin and antioxidants for the treatment of nonalcoholic fatty liver disease: the St Francis Heart Study randomized clinical trial.
    The American journal of gastroenterology, 2011, Volume: 106, Issue:1

    Topics: Administration, Oral; Aged; Analysis of Variance; Antioxidants; Ascorbic Acid; Atorvastatin; California; Confidence Intervals; Dose-Response Relationship, Drug; Double-Blind Method; Drug Administration Schedule; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Middle Aged; Multivariate Analysis; Non-alcoholic Fatty Liver Disease; Pyrroles; Risk Assessment; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin D

2011
Effect of atorvastatin, vitamin E and C on nonalcoholic fatty liver disease: is the combination required?
    The American journal of gastroenterology, 2011, Volume: 106, Issue:1

    Topics: Antioxidants; Ascorbic Acid; Atorvastatin; Confidence Intervals; Drug Therapy, Combination; Fatty Liver; Female; Follow-Up Studies; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Male; Non-alcoholic Fatty Liver Disease; Odds Ratio; Pyrroles; Risk Assessment; Sensitivity and Specificity; Severity of Illness Index; Tomography, X-Ray Computed; Treatment Outcome; Vitamin A

2011
Paraoxonase-1 activity, malondialdehyde and glutathione peroxidase in non-alcoholic fatty liver disease and the effect of atorvastatin.
    Arab journal of gastroenterology : the official publication of the Pan-Arab Association of Gastroenterology, 2011, Volume: 12, Issue:2

    Topics: Adult; Alanine Transaminase; Anticholesteremic Agents; Aryldialkylphosphatase; Aspartate Aminotransferases; Atorvastatin; Cholesterol; Cross-Sectional Studies; Disease Progression; Fatty Liver; Female; Glutathione Peroxidase; Hepatitis; Heptanoic Acids; Humans; Lipid Peroxidation; Lipoproteins, HDL; Lipoproteins, LDL; Male; Malondialdehyde; Middle Aged; Non-alcoholic Fatty Liver Disease; Obesity; Oxidative Stress; Pyrroles; Risk Factors; Triglycerides

2011

Other Studies

24 other study(ies) available for pyrroles and Fatty Liver, Nonalcoholic

ArticleYear
Structural Basis for Anti-non-alcoholic Fatty Liver Disease and Diabetic Dyslipidemia Drug Saroglitazar as a PPAR α/γ Dual Agonist.
    Biological & pharmaceutical bulletin, 2021, Volume: 44, Issue:9

    Topics: Binding Sites; Crystallography, X-Ray; Diabetes Mellitus, Type 2; Dyslipidemias; Humans; Hypolipidemic Agents; Lipid Metabolism; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Protein Domains; Pyrroles; Recombinant Proteins

2021
Saroglitazar improved hepatic steatosis and fibrosis by modulating inflammatory cytokines and adiponectin in an animal model of non-alcoholic steatohepatitis.
    BMC pharmacology & toxicology, 2021, 10-01, Volume: 22, Issue:1

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Cytokines; Disease Models, Animal; Gene Expression Regulation; Liver; Liver Cirrhosis; Male; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Rats, Wistar

2021
Saroglitazar - A Potential Therapeutic Option in Treating NASH? [Letter].
    Drug design, development and therapy, 2021, Volume: 15

    Topics: Humans; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles

2021
Saroglitazar Improves Transaminases and Elastography in Patients with Diabetic Dyslipidemia and Non-Alcoholic Fatty Liver Disease.
    The Journal of the Association of Physicians of India, 2020, Volume: 68, Issue:1

    Topics: Diabetes Mellitus; Dyslipidemias; Elasticity Imaging Techniques; Humans; Liver; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles; Transaminases

2020
The PPAR α/γ Agonist Saroglitazar Improves Insulin Resistance and Steatohepatitis in a Diet Induced Animal Model of Nonalcoholic Fatty Liver Disease.
    Scientific reports, 2020, 06-09, Volume: 10, Issue:1

    Topics: Animals; Diet, High-Fat; Disease Models, Animal; Dyslipidemias; Endoplasmic Reticulum Stress; Gene Expression Profiling; Insulin Resistance; Liver; Liver Cirrhosis; Metabolomics; Non-alcoholic Fatty Liver Disease; Phenylpropionates; PPAR alpha; PPAR gamma; Pyrroles; Signal Transduction

2020
Saroglitazar in patients with non-alcoholic fatty liver disease and diabetic dyslipidemia: a prospective, observational, real world study.
    Scientific reports, 2020, 12-03, Volume: 10, Issue:1

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Diabetes Mellitus, Type 2; Dyslipidemias; Female; Humans; Liver; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Prospective Studies; Pyrroles; Regression Analysis

2020
The PKM2 activator TEPP-46 attenuates MCD feeding-induced nonalcoholic steatohepatitis by inhibiting the activation of Kupffer cells.
    European review for medical and pharmacological sciences, 2021, Volume: 25, Issue:11

    Topics: Animals; Choline; Cytokines; Diet; Inflammasomes; Kupffer Cells; Liver; Male; Methionine; Mice, Inbred C57BL; NLR Family, Pyrin Domain-Containing 3 Protein; Non-alcoholic Fatty Liver Disease; Pyridazines; Pyrroles; Pyruvate Kinase

2021
Saroglitazar for the Treatment of NASH: The Peroxisome Proliferator-Activated Receptor Story Goes On!
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:4

    Topics: Humans; Non-alcoholic Fatty Liver Disease; Peroxisome Proliferator-Activated Receptors; Phenylpropionates; Pyrroles

2021
Letter to the Editor: Saroglitazar for Treatment of NAFLD and NASH.
    Hepatology (Baltimore, Md.), 2021, Volume: 74, Issue:6

    Topics: Humans; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles

2021
Dual PPARα/γ agonist saroglitazar improves liver histopathology and biochemistry in experimental NASH models.
    Liver international : official journal of the International Association for the Study of the Liver, 2018, Volume: 38, Issue:6

    Topics: Alanine Transaminase; Animals; Aspartate Aminotransferases; Biomarkers; Diet, High-Fat; Fenofibrate; Hep G2 Cells; Humans; Kupffer Cells; Liver; Male; Mice; Mice, Inbred C57BL; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pioglitazone; PPAR alpha; Pyrroles; Tumor Necrosis Factor-alpha

2018
Saroglitazar Deactivates the Hepatic LPS/TLR4 Signaling Pathway and Ameliorates Adipocyte Dysfunction in Rats with High-Fat Emulsion/LPS Model-Induced Non-alcoholic Steatohepatitis.
    Inflammation, 2019, Volume: 42, Issue:3

    Topics: Adipocytes; Animals; Down-Regulation; Lipopolysaccharides; Liver; Non-alcoholic Fatty Liver Disease; Phenylpropionates; Pyrroles; Rats; Signal Transduction; Toll-Like Receptor 4

2019
Pharmacological cholesterol lowering reverses fibrotic NASH in obese, diabetic mice with metabolic syndrome.
    Journal of hepatology, 2013, Volume: 59, Issue:1

    Topics: Adiponectin; Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Diabetes Complications; Drug Therapy, Combination; Ezetimibe; Fatty Liver; Female; Heptanoic Acids; Insulin; Liver; MAP Kinase Signaling System; Metabolic Syndrome; Mice; Mice, Mutant Strains; Mice, Obese; Non-alcoholic Fatty Liver Disease; Pyrroles

2013
Cardiovascular risk reduction with combination of anti-atherosclerotic medications in younger and older patients.
    Current medical research and opinion, 2013, Volume: 29, Issue:7

    Topics: Age Factors; Amlodipine; Antihypertensive Agents; Atherosclerosis; Cardiovascular Diseases; Cholesterol, LDL; Drug Combinations; Fatty Liver; Heptanoic Acids; Humans; Metabolic Diseases; Non-alcoholic Fatty Liver Disease; Patient Compliance; Pyrroles; Risk; Risk Reduction Behavior

2013
Are statins 'IDEAL' for non-alcoholic fatty liver disease?
    Current medical research and opinion, 2014, Volume: 30, Issue:2

    Topics: Atorvastatin; Carcinoma, Hepatocellular; Cardiovascular Diseases; Dyslipidemias; Female; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Inflammation; Liver; Liver Neoplasms; Male; Metabolic Syndrome; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Triglycerides

2014
APOE*3Leiden.CETP transgenic mice as model for pharmaceutical treatment of the metabolic syndrome.
    Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

    Topics: 11-beta-Hydroxysteroid Dehydrogenase Type 1; Animals; Apolipoprotein E3; Atorvastatin; Cholesterol Ester Transfer Proteins; Disease Models, Animal; Fenofibrate; Glucagon-Like Peptide 1; Heptanoic Acids; Humans; Hypoglycemic Agents; Hypolipidemic Agents; Liraglutide; Male; Metabolic Syndrome; Mice, Transgenic; Niacin; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Rosiglitazone; Thiazolidinediones

2014
Cholesterol-lowering drugs cause dissolution of cholesterol crystals and disperse Kupffer cell crown-like structures during resolution of NASH.
    Journal of lipid research, 2015, Volume: 56, Issue:2

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Azetidines; Cholesterol; Ezetimibe; Female; Heptanoic Acids; Inflammasomes; Kupffer Cells; Liver; Mice; Mice, Mutant Strains; Non-alcoholic Fatty Liver Disease; Pyrroles

2015
[Negative effects of termination statinotherapy in patients after acute coronary event with concominent non-alcoholic steatohepatitis].
    Likars'ka sprava, 2014, Issue:11

    Topics: Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Administration Schedule; Female; Fluorobenzenes; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolemia; Male; Middle Aged; Myocardial Infarction; Non-alcoholic Fatty Liver Disease; Pyrimidines; Pyrroles; Recurrence; Rosuvastatin Calcium; Sulfonamides; Triglycerides

2014
Reduction of liver fructokinase expression and improved hepatic inflammation and metabolism in liquid fructose-fed rats after atorvastatin treatment.
    Toxicology and applied pharmacology, 2011, Feb-15, Volume: 251, Issue:1

    Topics: Animals; Atorvastatin; Basic Helix-Loop-Helix Leucine Zipper Transcription Factors; Cyclic AMP-Dependent Protein Kinases; Dietary Carbohydrates; Disease Models, Animal; Down-Regulation; Fatty Acids; Fatty Liver; Fructokinases; Fructose; Gene Expression Regulation; Hepatitis; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypertriglyceridemia; I-kappa B Proteins; Inflammation Mediators; Lipid Metabolism; Liver; Male; Metallothionein; Necrosis; NF-kappa B; Non-alcoholic Fatty Liver Disease; Oxidation-Reduction; Phosphorylation; Pyrroles; Rats; Rats, Sprague-Dawley; Triglycerides

2011
Metformin and atorvastatin combination further protect the liver in type 2 diabetes with hyperlipidaemia.
    Diabetes/metabolism research and reviews, 2011, Volume: 27, Issue:1

    Topics: Animals; Anticholesteremic Agents; Atorvastatin; Body Weight; C-Reactive Protein; Diabetes Complications; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Drug Combinations; Fatty Liver; Heptanoic Acids; Hyperlipidemias; Hypoglycemic Agents; Insulin Resistance; Interleukin-6; Liver; Metformin; Non-alcoholic Fatty Liver Disease; Oxidative Stress; Pyrroles; Rats; Rats, Inbred Strains; Tumor Necrosis Factor-alpha

2011
Comparison of dietary control and atorvastatin on high fat diet induced hepatic steatosis and hyperlipidemia in rats.
    Lipids in health and disease, 2011, Jan-26, Volume: 10

    Topics: Animals; Atorvastatin; Combined Modality Therapy; Dietary Fats; Fatty Liver; Gene Expression Regulation; Heptanoic Acids; Hydroxymethylglutaryl CoA Reductases; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Lipid Metabolism; Lipids; Liver; Male; Non-alcoholic Fatty Liver Disease; Organ Size; PPAR alpha; Pyrroles; Rats; Rats, Sprague-Dawley; Sterol Regulatory Element Binding Protein 1; Transaminases

2011
Atorvastatin improves disease activity of nonalcoholic steatohepatitis partly through its tumour necrosis factor-α-lowering property.
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:6

    Topics: Adiponectin; Adult; Alanine Transaminase; Anticholesteremic Agents; Aspartate Aminotransferases; Atorvastatin; Blood Glucose; Body Mass Index; Cholesterol, HDL; Cholesterol, LDL; Collagen Type IV; Dyslipidemias; Fatty Liver; Female; gamma-Glutamyltransferase; Heptanoic Acids; Humans; Insulin Resistance; Male; Middle Aged; Non-alcoholic Fatty Liver Disease; Pyrroles; Regression Analysis; Severity of Illness Index; Triglycerides; Tumor Necrosis Factor-alpha

2012
Atorvastatin protects obese mice against hepatic ischemia-reperfusion injury by Toll-like receptor-4 suppression and endothelial nitric oxide synthase activation.
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:8

    Topics: Administration, Oral; Animals; Atorvastatin; Cell Adhesion Molecules; Cytokines; Cytoprotection; Disease Models, Animal; Down-Regulation; Drug Administration Schedule; Enzyme Activation; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Injections, Intravenous; Liver; Male; Mice; Mice, Obese; NF-kappa B; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; RNA, Messenger; Thromboxane B2; Time Factors; Toll-Like Receptor 4

2012
If steatosis is the atherosclerosis of the liver, are statins the "aspirin" for steatosis?
    Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver, 2012, Volume: 44, Issue:6

    Topics: Anticholesteremic Agents; Atorvastatin; Dyslipidemias; Fatty Liver; Female; Heptanoic Acids; Humans; Male; Non-alcoholic Fatty Liver Disease; Pyrroles; Tumor Necrosis Factor-alpha

2012
Enhancing organ pool by statins: is this the future?
    Journal of gastroenterology and hepatology, 2012, Volume: 27, Issue:8

    Topics: Animals; Atorvastatin; Fatty Liver; Heptanoic Acids; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Liver; Male; Nitric Oxide Synthase Type III; Non-alcoholic Fatty Liver Disease; Obesity; Pyrroles; Reperfusion Injury; Toll-Like Receptor 4

2012